Mike Patterson – CEO graphenefrontiers.com
Market Opportunity
$9.9B Biosensors:
1st Gen POC Diagnostics: Not Good Enough Limited sensitivity • Slow • Inaccurate •
ELISA GFET 100x- 1000x better Limit of Detection (LOD) 1-20pg/ml than ELISA Ability to Multiplex No (1 antibody per run) Yes May take hours for Speed Sample to results in minutes incubation and processing Cost Expensive Optical Readers All electronic, lower cost After sample obtained, Ease of Use Trained Lab Tech Needed the rest is automated Relies on secondary Specific and direct Specificity of detection detection antibody detection – all electronic Higher false positives
Next Gen POC Diagnostics: Quantum Leap
How it Works
Devices: GFET GFET = Graphene Field Effect Transistor
Why Graphene?
Conductive Heat Electricity
Impermeable and Hydrophobic
But will it scale?
Problem: Commercial Production 1) Low Volume 2) Expensive 3) Not Uniform 4) Harsh Chemicals
Breakthrough: Problem Solved 08
2010 1 cm 2 > $10,000
2012 1 cm 2 < $10
2015 1 cm 2 < $.01
Evidence and Traction
Demonstrated Results: Multiple Proteins • IL-6 • Borrelia burgdorferi • Osteopontin (OPN) • Salmonella Clear signal @ 1pg/mL (30 fM)
Proof of Concept Program: Troponin I
POC Diagnostics: Potential Partners
18 Team Graphene: Founders Mike Patterson – Chief Executive Officer A.T. Charlie Johnson, Ph.D. – Founder, Advisor
18 Bruce Willner – Chief Science Officer
18 Team Graphene – Product Team Ryan Mendoza Victoria Tsai, Ph.D. Paige Boehmcke NOW HIRING: - Electrical - Materials Science - Diagnostics Expert - Neuroscience Engineering - Clinical Research - Commercialization experience
19 Strong: Intellectual Property Core Patents Status (3): • 2010 PCT, U. Penn, Woodcock Washburn • Exclusive, all fields perpetual licenses • Global, w/sublicense rights • National Phase: US, EU, Korea, Japan, China, India • 2 x 2010 US Utility applications Additional IP (5): • Patent pending transfer method • Additional, complementary sensor IP under option
Grants Awarded to Date: $1,285,000
22 Equity Capital: Existing Funding 2012 seed round: $426,000 (common equity) Management Individual Angels
23 Capital Needs: Open Financing $1,200,000 convertible securities $731,000 closed to date Uses: Troponin I Proof of Concept Program: • Diagnostics expert (new hire) • Capital Equipment • Sensor production
Mike Patterson - CEO mike@graphenefrontiers.com (267) 223-5051
Recommend
More recommend
